

Itefat Hamzavi



OMB No. 0925-0001/0002 (Rev. 04/19 Approved Through 5/31/2019)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Itefat Husain Hamzavi, M.D., F.A.A.D.

eRA COMMONS USER NAME (credential, e.g., agency login): ihamzav1

POSITION TITLE: Senior Staff Physician

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
University of Michigan, Ann Arbor, MI	M.D.	05/1996	Dermatology
University of Michigan, Ann Arbor, MI	Bachelors	05/1992	Sociology
St. Joseph Mercy Hospital, Ann Arbor, MI	Internship	05/1997	Internal Medicine
Wayne State University, Detroit, MI	Residency	05/2000	Dermatology
University of British Columbia, Vancouver, Canada	Fellowship	05/2001	Lasers and Photomedicine

Statistics (Effective 1/2019)

H Index	30
Citations	2,504
Publications	120

A. Personal Statement

I am the co-director of the Multicultural section of Henry Ford Hospital's Dermatology department. This is one of the largest units of its kind in the United States and has led to advances in the care of pigmentary and follicular disorders. I am the lead physician for the Hidradenitis Clinic in the Department of Dermatology at Henry Ford Health System. In this clinic, I have treated over 3,500 patients with Hidradenitis Suppurativa (HS) and manage over 6,000 patients in our database. Many of these patients come to our group from around the world to receive cutting edge treatment offered by our institution. One such treatment is Carbon Dioxide Laser Excision Surgery and the Nd:YAG laser. I am one of two U.S. based physicians that offer this treatment that offers a tremendous quality of life improvement. This and other surgical treatments at the Nd:YAG laser treatment, developed at our center, afford us the ability to have a large resource of tissue specimens. We also have an excellent track record of collaboration and have assisted in the creation of HS clinics in North Carolina, Philadelphia, San Francisco and New York. Our group is quite cognizant of engaging our patients in

support groups and advocating for better treatments. Our center has sponsored the first and largest face to face HS support group in the country which is directed by our research manager. We have done this work while raising funds for our research through foundations and industry funded research that have our patients' direct input. We also have the first and largest vitiligo surgery center in the United States. This unit was established after foundation funded studies showed that MKTP (melanocyte keratinocyte transplants procedure) to be a safe and effective option. Our unit was also one of the lead sites in developing and implementing new protocols for the first new drug treatment of vitiligo. I was also first author on the primary outcome measure for vitiligo, the VASI score. We are also the coordinating center for the Global Vitiligo Foundation (formerly the Vitiligo Working Group) which brings patients, clinicians, regulators and industry together to collaborate on finding better treatments. Despite these limited resources we have a track record of applying and developing new treatment options for even the most challenging HS and vitiligo cases. I am moved by the patients that I see in my clinic that have come to me after delay in diagnosis and disease management, and I am motivated to do further research on this disease. Because of our ability to integrate clinical solutions with patient aspirations while understanding the limitations of our existing treatment options we are an ideal part of any research collaboration that involves HS or vitiligo.

In addition to this work we are home to an active photobiology research unit that was initiated by Dr. Henry Lim. As principal investigator, I lead our team in describing the role of visible light in pigment production in darker skin types. This work is in the top 1% of most cited article in the dermatologic literature over the past 15 years. In conjunction with our physicist, Indermeet Kohli, we have shown how visible light potentiates the effects of UV light in both light and dark skinned individuals. This has led to multiple new fields of study and the growth of our research team.

B. Positions and Honors

FACULTY APPOINTMENTS:

May 2005 – Present	Senior Staff Physician, Department of Dermatology, Henry Ford Health System, Henry Ford Medical Center
August 2003- Present	Clinical Associate Professor (since 4/2019), Wayne State University, Detroit, MI
2003 – 2006	Clinical Course Director, Dermatology Section on 2 nd year curriculum, Wayne State University, Detroit, MI
January 2002 - Present	Instructor, Clinical, Department of Dermatology, Wayne State University

PROFESSIONAL MEMBERSHIP:

- American Medical Association
- American Academy of Dermatology
- American Society for Lasers in Medicine and Surgery
- The Photomedicine Society
- Canadian Dermatology Association
- Dermatology Foundation

- Michigan State Medical Society
- Skin of Color Society
- Global Vitiligo Foundation – Board Member (Formerly: Vitiligo Working Group)
- Hidradenitis Suppurativa Foundation - President

Honors and Appointments

2018	Resident Teaching Award, Henry Ford Health System, Department of Dermatology
2018	Co-Chair Vitiligo International Symposium
2018	Premier Rating of Vitiligo, Researcher
2018	ASP Co-Chair
2017	Class 2018 (39) – Leadership Detroit
2017	Residency Teacher of the Year Award, Henry Ford Health System
2017	Founding Chair Emeritus - ISPU
2015	Chairman of the Vitiligo Working Group fourth annual convening
2015	Nominated to Chair two sessions at the World Congress of Dermatology Meeting in Vancouver British Columbia. This is the largest gathering of dermatologists in the world.
2014	Hour Magazine, Best Doctors and Castle Connelly list of Top American Physicians
2013	Kathryn Quinlan Humanism Award
2012	First author of most cited article on MDInx Feb 2012

2012	Principal Investigator for Henry Ford team awarded grant by Estee Lauder to develop and evaluate studies in pigmentation
2011	Selected by Best Doctors as one of the top 5% of US physicians
2010	Selected by Hour Magazine as one of Detroit's Best Physicians
2010	Selected by Best Doctors as one of the top 5% of US physicians
2010	Mentor on Acne Rosacea Society Grant to Pranita Vemulapalli for the study of Hidradenitis Suppurativa
2008	Cutting Edge ASDS Research Award for work in Hidradenitis Suppurativa
2008	Bassel Mahmoud, our clinical fellow, has been selected by the AAD for presentation at the Residents/ Fellow symposium and thus qualifies for the Fox Award.
2007	Cutting Edge ASDS Research Award for work on Vitamin D and Skin Cancer.
2007	Cutting Edge ASDS Award Prospective Controlled Study of the Efficacy of Nd: YAG Laser for Hidradenitis Suppurativa

C. Contribution to Science

- After witnessing the Nd:YAG laser as an effective treatment for a patient with dissecting cellulitis, I decided to attempt laser hair removal as a treatment for Hidradenitis Suppurativa. I was the first physician to discover the benefit of Nd:YAG laser treatment for Hidradenitis Suppurativa. The results of this study were published in 2009. Today, Nd:YAG is used in many worldwide centers as treatment for Hidradenitis Suppurativa and is beginning to be reimbursed by some insurance companies.
 - Tierney E, Mahmoud BH, Hexsel C, Ozog D, **Hamzavi I.** - Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. - **Dermatol Surg.** 2009 Aug; 35 (8): 1188-98
- The prevalence of metabolic syndrome in patients with hidradenitis suppurativa was established by my research via an extensive review of over 600 cases of hidradenitis suppurativa. This research highlights that in addition to treating the skin, health care practitioners should screen patients with hidradenitis suppurativa for metabolic syndrome
 - Gold D, Reeder V, **Hamzavi I** – The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. - J Am Acad Dermatol. 2014 Apr;70(4):699-703. doi: 10.1016/j.jaad.2013.11.014. Epub 2014 Jan 13.
- Many patients with Hidradenitis Suppurativa will experience a delay of decades before achieving a diagnosis with correct treatment. This study established that the delay in treatment is a global problem.
 - Saunte DM¹, Boer J², Stratigos A³, Szepietowski JC⁴, **Hamzavi I**⁵, Kim KH⁶, Zarchi K¹, Antoniou C³, Matusiak L⁴, Lim HW⁵, Williams M⁵, Kwon HH⁶, Gürer MA⁷, Mammadova F⁷, Kaminsky A⁸, Prens E⁹, van der Zee HH⁹, Bettoli V¹⁰, Zauli S¹⁰, Hafner J¹¹, Lauchli S¹¹, French LE¹¹, Riad H¹², El-Domyati M¹³, Abdel-Wahab H¹³, Kirby B¹⁴, Kelly G¹⁴, Calderon P¹⁵, Del Marmol V¹⁶, Benhadou F¹⁶, Revuz J¹⁷, Zouboulis CC¹⁸, Karagiannidis I¹⁸, Sartorius K¹⁹, Hagströmer L¹⁹, McMeniman E²⁰, Ong N²⁰, Dolenc-Voljc M²¹, Mokos ZB²², Borradori L²³, Hunger RE²³, Sladden C²⁴, Scheinfeld N²⁵, Moftah N²⁶, Emtestam L²⁷, Lapins J²⁷, Doss N²⁸, Kurokawa I²⁹, Jemec GB¹. **Br J Dermatol.** 2015 Jul 21. doi: 10.1111/bjd.14038. [Epub ahead of print]

- I was an investigator for a ground-breaking study using afamelanotide implants as a treatment for Erythropoietic Protoporphyrria. This work concluded that afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.
 - [Langendonk JG¹](#), [Balwani M](#), [Anderson KE](#), [Bonkovsky HL](#), [Anstey AV](#), [Bissell DM](#), [Bloomer J](#), [Edwards C](#), [Neumann NJ](#), [Parker C](#), [Phillips JD](#), [Lim HW](#), **Hamzavi I**, [Deybach JC](#), [Kauppinen R](#), [Rhodes LE](#), [Frank J](#), [Murphy GM](#), [Karstens FP](#), [Sijbrands EJ](#), [de Rooij FW](#), [Lebwohl M](#), [Naik H](#), [Goding CR](#), [Wilson JH](#), [Desnick RJ](#). **N Engl J Med**. 2015 Jul 2;373(1):48-59. doi: 10.1056/NEJMoa1411481.

- As a researcher in both follicular and pigmentation disorders, I contributed to work that looked at vitiligo as an excellent model for studying degenerative and autoimmune processes and for testing novel approaches in regenerative medicine.
 - Mauro Picardo, Maria L. Dell'Anna, Khaled Ezzedine, **Iltefat Hamzavi**, John E. Harris, Davinder Parsad and Alain Taieb, **Nature Reviews**, Disease Primer15011 doi:10.1038/nrdp.2015.11 Published online

- In my continued work as researcher of vitiligo, we established the comorbid association of thyroid disease, inflammatory neurologic diseases with vitiligo. This was highlighted in the American Academy of Dermatology Press Release in March 2015. This work was recently accepted for publication in the Journal of the American Academy of Dermatology (JAAD). A print date was not available at the time of this biosketch.
 - <https://www.aad.org/stories-and-news/news-releases/vitiligo-s-impact-goes-beyond-skin>

- I contributed to research looking at Th17 cells. Th17 cells have been identified to be implicated in human autoimmune diseases. In this study, the frequencies of peripheral blood Th17 cells and serum levels of IL-17A and Th17 cell-related cytokines were examined in 45 patients with active NSV compared to 45 race-, gender-, and age-matched healthy controls. Our results showed increased circulating Th17 cell frequencies and elevated serum IL-17A, TGF-β1, and IL-21 levels in patients with NSV.
 - Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. [Zhou L](#), [Shi YL](#), [Li K](#), [Hamzavi I](#), [Gao TW](#), [Huggins RH](#), [Lim HW](#), [Mi QS](#). **Pigment Cell Melanoma Res**. 2015 May;28(3):324-9. doi: 10.1111/pcmr.12355. Epub 2015 Feb 13

- Our article on the surgical treatment of vitiligo resulted in the establishment of the first and one of the largest vitiligo surgical units in the United States. It also has resulted in a model to understand disease stability.

- [Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States](#). Huggins RH, Henderson MD, Mulekar SV, Ozog DM, Kerr HA, Jabobsen G, Lim HW, Hamzavi IH. J Am Acad Dermatol. 2012 May;66(5):785-93. doi: 10.1016/j.jaad.2011.05.002. Epub 2011 Aug 23. PMID:21864935
- We submitted a letter to the editor of the Journal of Investigative Dermatology (JID) regarding the experience of our center with certain ethnic populations and hidradenitis suppurativa. Our research supported the teaching that HS is more common in those of African descent.
 - Ethnicity and Hidradenitis Suppurativa, Reeder V, Mahan M, **Hamzavi I**, Journal of Investigative Dermatology (2014) **134**, 2842–2843; doi:10.1038/jid.2014.220; published online 5 June 2014
- Our research on the use of biologics and hidradenitis suppurativa highlights the need for vigilant preventative measures and continuity of care in patients with HS with severe, chronic disease, and those on biological therapy.
 - Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience. [Zhang J](#), [Reeder VJ](#), **Hamzavi IH**, [Br J Dermatol](#). 2014 Dec;171(6):1600-2. doi: 10.1111/bjd.13186. Epub 2014 Oct 27.
- Our work on visible light and pigmentation is in the top 1% of citations within the dermatologic literature for the past 15 years.
 - .Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, **Hamzavi I**. - [Impact of Long-Wavelength UVA and Visible Light on Melanocompetent Skin](#) - J Invest Dermatol. 2010 Apr 22.

Complete List of Published Work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=iltefat+hamzavi>

D. Research Support

I currently have federal sponsored research support. Other research support achieved is by industry sponsors or institutional funding.